Background: Since its emergence in December 2019, SARS-CoV-2, the coronavirus responsible for COVID-19, has spread across the globe, infected millions of people and caused several million deaths. One promising intervention to combat the ongoing COVID-19 pandemic is mesenchymal stem/stromal cells (MSCs). Many trials were registered at the onset of the pandemic to determine the safety and efficacy of MSCs in COVID-19 patients. However, currently published studies are underpowered to provide an estimate of safety and efficacy on their own. Thus, a living systematic review (SR) is needed to establish the benefits and drawbacks of MSCs for COVID-19 on a relevant timescale. Methods: Systematic literature searches were conducted on Feb 3rd, 2021 and November 15th, 2021 to identify all English-language, full-text, clinical studies examining MSCs to treat COVID-19. (PROSPERO:CRD42021225431). Findings/Conclusions: Our first search identified nine studies (4 controlled) examining the use of MSC derived products to treat COVID-19 patients. This first iteration of our SR revealed that MSCs were safe and reduced mortality in patients suffering from COVID-19. However, risk of bias (RoB) and poor adherence to ISCT cell product characterization guidelines limited the strength of our conclusions. In the second iteration of our living SR, we only included controlled studies to strengthen our conclusions. We identified eleven controlled studies (5 RCTs). MSCs continued to demonstrate safety and efficacy at reducing mortality at study endpoint (RR: 0.50 [0.34 to 0.75, 95% CI, p=0.0006, I2=0%]). However, we continued to encounter barriers which prevented us from drawing more definitive conclusions. A master protocol appears necessary to facilitate the accelerated accumulation of high-quality evidence where standardized outcome reporting and consistent product characterization allow for a more definitive and timely estimate regarding the safety and efficacy of this cell-based therapy for COVID-19.

<p>In the year of 2020, an international pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has afflicted tens of millions of people’s life also disrupting global economics. Diagnostic testing is an important part of ensuring public health until a vaccine that has been shown to be safe and effective is made available to the general public. Most tests for detecting COVID-19 utilize quantitative polymerase chain reaction (qPCR) assays, which is a specific and relatively simple quantitative assay that could provide adequate sensitivity for diagnosing early infection. Although powerful, these lab-based molecular assays have a significant lag time, usually several days before receiving results. To satisfy the needs of different purposes (diagnostics, screening, and surveillance), a unified approach is impractical. This thesis presents an alternative testing method supporting the current procedure of point of care (POC) testing and in community testing. This paper-based test overcomes the limitations of current testing methods by utilizing reverse-transcription loop-mediated isothermal amplification (RT-LAMP) and receiving the result on-site by a color change in the presence of the virus within 60 minutes. The test utilizes untreated freshly collected saliva, a less invasive specimen, as the sample and possesses a limit of detection (LoD) of 200 copies of virus per microliter of whole saliva with an analytical sensitivity of 97% and analytical specificity of 100%. The test requires minimal operator training and could be fabricated on a large-scale using roll-to-roll methods. Since the test is based on nucleic acids, the testing platform itself lends to further applications <a>including food safety monitoring, animal diagnostic, etc. simply by changing the specific primers</a>. </p>

Introduction: The high transmissibility and lethality of the novel coronavirus SARS-CoV-2 (COVID-19) have been catastrophic. Acute kidney injury (AKI) is one of the frequent complications in patients with respiratory insufficiency caused by the virus. The pathogenic mechanism is based on the binding of its S-proteins to the angiotensin-converting enzyme (ACE) receptors, which will trigger a cellular damage. A podocyte and tubular compromise are found in the kidneys which can lead to tubular necrosis and the consequent AKI. Objectives: The objective of this report is to identify the main risk factor to develop AKI in patients infected with SARS-CoV-2 with critical acute respiratory distress. Patients and Methods: We performed this report study, collecting data from 48 ICU patients. Data from 13 of them who developed AKI and needed renal replacement therapy (RRT)were analyzed. Clinical characteristics and laboratory findings were reported using STATA 10.0. Results: AKI was present in 27.08% of patients, mostly male (92.3%) with a mean age of 63.8 years old. Hypertension, diabetes and obesity were the main comorbidities in those patients. Additionally, the meantime between admission and AKI diagnosis was 2.69 days. All patients showed fibrinogen, D-dimer, ALT and values above normal range. Mortality was seen in 61.5% of patients. Conclusion: This report tries to show AKI as an important clinical manifestation in critically ill patients infected with SARS-CoV-2, with high mortality. Further studies are needed to demonstrate if there are independent risk factors. / Revisión por pares

The coronavirus disease 2019 (COVID-19) has led to more than 3,000,000 deaths globally. During the first year of the pandemic, countries have focused their response strategies on non-pharmaceutical interventions (NPIs) such as lockdowns and use of facial coverings. Because of collateral effects (psycho-social, and economical) by NPIs, investigating their effectiveness is increasingly important for optimal policies. The aim of this study is to investigate whether varying degrees of response strategies affect the rate of change in mortality at specific time points in the epidemic. The containment and health index (CHI) is used to identify the degree of response measures adopted by each country. Six time points around the peak of daily mortality are identified for the first two epidemiological waves for 40 European countries. The response was then correlated to the rate of change of mortality observed over one week 26 days later (time lag for the intervention to take effect). Spearman’s rank correlation coefficient was used for the unadjusted analysis, and multiple linear regression is used in the adjusted analysis. The intensity of CHI reduced the rate of increase of mortality before the first epidemic peak but had no detectable effect at any other time point. Different covariates and interactions between CHI and covariates such as population density and GDP, affected the rate of change of mortality at different time points during the two waves. NPIs may be effective, as suggested by a significant effect of CHI on mortality early in the first wave. However, the effect is not consistent across time points, and the extent of collateral damage suggests a closer look at other factors influencing the epidemic is necessary.

Introduktion: Coronavirus är RNA-virus med ett lipidhölje som är täckt utav karaktäristiska spikprotein. De mest kända coronavirusvarianterna är SARS-CoV-1 som var aktiv mellan 2002-2004, MERS-CoV som har varit aktiv sedan 2012 och SARS-CoV-2 som har varit aktiv sedan 2019–tillsvidare. SARS-CoV-2 infektionen betecknades januari 30 2020 som en pandemi. Flera läkemedelsföretag har forcerat ??? till att framställa vaccin riktad mot SARS-CoV-2, “The United States Food and Drug Administration” (FDA) och “European Medicines Agency” (EMA) har nödgats att ge ut “Emergency Use Authorization (EUA) i hopp om att få kontroll på dess spridining. Syfte och mål: Syftet med arbetet är att undersöka säkerheten och effektiviteten hos de EMA-godkända vaccinerna riktade mot SARS-CoV-2. Metod: Studierna för vardera vaccin hittades och valdes ut genom World Health Organizations (WHO) “Draft landscape and tracker of COVID-19 candidate vaccines”. Totalt inkluderades åtta studier baserade på tio kliniska prövningar som undersökte säkerheten och effektiviteten hos de fyra ledande vaccinerna från Pfizer BioNTech, Moderna, AstraZeneca och Johnson &amp; Johnson. Resultat: De fyra undersökta vaccinerna visade en god säkerhet utan grövre biverkningar. De vanligaste biverkningarna hos samtliga vaccin var lokal smärta, trötthet och huvudverk. Dessa biverkningar varade mellan en till två dagar efter vaccination och var till större del milda. Större skillnader kunde ses hos de olika vaccinernas effektivitet, Pfizer BioNTech och Modernas mRNA-vacciner visade på effektiviteter runt 95% medan AstraZeneca och Johnson &amp; Johnsons adenovirus-vektor-vacciner visade på effektiviteter runt 66-70%. Diskussion: Inga större skillnader i säkerhet kunde ses mellan de undersökta vaccinerna. AstraZeneca använde ett influensa vaccin istället för isoton vattenlösning till deras kontrollgrupper. Detta kan ha haft en påverkan på placebo och resultaten från deras prövningar. En tydlig skillnad i effektivitet kunde ses mellan de olika vaccintyperna, vilket har ett stort inflytande på hur lätt man kan inducera flockimmunitet hos en befolkning. Eftersom flockimmunitet har en stor roll i både att bromsa spridningen men även i att förebygga förekomsten av nya virus varianter så bör endast mRNA vacciner rekomenderas om möjligt. / Introduction: Coronaviruses are RNA viruses with a lipid envelope that is covered by characteristic spike protein. The most well-known coronaviruses are SARS-CoV-1 which were active between 2002-2004, MERS-CoV which is active since 2012 and SARS-CoV-2 which is active since 2019. SARS-CoV-2 was designated a pandemic January 30, 2020. Several pharmaceutical companies have been rushing to produce vaccines targeting SARS-CoV-2, The United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have had to issue Emergency Use Authorization (EUA) in the hope of gaining control of its spread. Objective: The purpose of this study is to investigate the safety and efficacy of the EMA-approved vaccines targeting SARS-CoV-2. Method: The studies for each vaccine were found and selected through the World Health Organizations' (WHO) "Draft landscape and tracker of COVID-19 candidate vaccines". A total of eight studies were included based on ten clinical trials examining the safety and efficacy of the four leading vaccines from Pfizer BioNTech, Moderna, AstraZeneca and Johnson &amp; Johnson. Results: The four vaccines examined showed good safety without any serious side effects, the most common side effects with all vaccines were local pain, fatigue, and headache. These side effects lasted between one to two days after vaccination and were mostly mild. Larger differences could be seen in the efficacy of the different vaccines, with Pfizer BioNTech and Moderna's mRNA vaccines showing efficacies of around 95%. While AstraZeneca and Johnson &amp; Johnson's adenovirus vector vaccines showed efficacies of around 66-70%. Discussion: No major differences in safety could be seen between the vaccines examined. AstraZeneca used an influenza vaccine instead of isotonic aqueous solution for their control groups, this may have had an impact on placebo and thus the results of their trials. A clear difference in efficacy could be seen between the different types of vaccines. This has a great influence on how easily one could induce herd immunity to a population. Herd immunity plays a major role in both slowing the spread but also in preventing the occurrence of new virus variants, therefore mRNA vaccines should be recommended if possible.

El desarrollo y producción de vacunas seguras y eficaces contra la enfermedad por coronavirus 2019 (COVID- 19) ofrece la esperanza para el control de la pandemia actual. Los eventos adversos posteriores a la inmunización son respuestas indeseadas o acontecimientos involuntarios que siguen a la vacunación, y que deben ser cuidadosamente vigilados, ya que todas las vacunas, incluyendo las desarrolladas contra el SARSCoV- 2, requieren cumplir con los criterios de seguridad para su administración en humanos. Se recopiló la información de la base de datos de PubMed/Medline durante los meses de agosto de 2020 a noviembre de 2021. La mayoría de los eventos adversos identificados en los ensayos clínicos fueron leves o moderados; sin embargo, se identificaron eventos trombóticos asociados a algunas vacunas basadas en vectores virales contra la COVID-19 en estudios de seguimiento, aunque se requiere la conclusión de los distintos estudios en curso y vigilancia poscomercialización para determinar todos los posibles eventos adversos y de especial interés.

Se describe la evidencia actual del efecto del SARS-CoV-2 a nivel de tejido renal. Se realizó una revisión narrativa de los artículos publicados en SCOPUS y PUBMED hasta septiembre de 2020. Los resultados se dividieron en las siguientes secciones: evidencia del efecto directo del virus en el riñón, mecanismos de invasión celular, mecanismos de injuria celular y las potenciales implicaciones terapéuticas de estos hallazgos. El SARS-CoV-2 invade las células del túbulo proximal y los podocitos, a través del receptor ECA-2. La invasión y replicación viral podrían producir daño mediante un efecto citopático directo aunado a un daño mediado por la respuesta inmune. Debido a la expresión celular de ECA-2, se ha propuesto a los Inhibidores del Sistema Renina–Angiotensina–Aldosterona como un potencial tratamiento contra la COVID-19. Sin embargo, a la fecha, la evidencia no apoya su uso. / We describe evidence on SARS-CoV-2 effect on the kidney. We carried a narrative review of articles published in SCOPUS and PUBMED until September 2020. The results were divided into six topics: evidence of direct effect of virus on the kidney, mechanisms of cellular invasion, mechanisms of kidney injury, and potential therapeutic implications. SARS-Cov-2 gains access to proximal tubule cells and podocytes via ACE-2 receptors. Viral invasion and replication may induce kidney damage through a direct cytopathic effect and immune-mediated damage. Due to ACE-2 cellular expression, Renin–Angiotensin–Aldosterone System Inhibitors have been proposed as potential treatment for COVID-19. However, current evidence does not support its therapeutic use. / Trabajo de investigación

Introduction The rapid expansion of the novel SARS-CoV-2 virus has raised serious public health concerns due to the possibility of misdiagnosis in regions where arboviral diseases are endemic. We performed the first study in northern Peru to describe the detection of SARSCoV-2 IgM antibodies in febrile patients with a suspected diagnosis of dengue and chikungunya fever. Materials and methods A consecutive cross-sectional study was performed in febrile patients attending primary healthcare centers from April 2020 through March 2021. Patients enrolled underwent serum sample collection for the molecular and serological detection of DENV and CHIKV. Also, serological detection of IgM antibodies against SARS-CoV-2 was performed. Results 464 patients were included during the study period, of which (40.51%) were positive for one pathogen, meanwhile (6.90%) presented co-infections between 2 or more pathogens. The majority of patients with monoinfections were positive for SARS-CoV-2 IgM with (73.40%), followed by DENV 18.09% and CHIKV (8.51%). The most frequent co-infection was DENV + SARS-CoV-2 with (65.63%), followed by DENV + CHIKV and DENV + CHIKV + SARSCoV-2, both with (12.50%). The presence of polyarthralgias in hands (43.75%, p<0.01) and feet (31.25%, p = 0.05) were more frequently reported in patients with CHIKV monoinfection. Also, conjunctivitis was more common in patients positive for SARS-CoV-2 IgM (11.45%, p<0.01). The rest of the symptoms were similar among all the study groups. Conclusion SARS-CoV-2 IgM antibodies were frequently detected in acute sera from febrile patients with a clinical suspicion of arboviral disease. The presence of polyarthralgias in hands and feet may be suggestive of CHIKV infection. These results reaffirm the need to consider SARS-CoV-2 infection as a main differential diagnosis of acute febrile illness in arboviruses endemic areas, as well as to consider co-infections between these pathogens. Copyright: / Revisión por pares

Cette thèse s’inscrit dans le cadre général de la dépollution d’effluents gazeux faiblement chargés en Composés Organiques Volatils (COV). L’étude concerne l'oxydation de trois COV cibles (méthane, propène, et toluène) dans l'air à la pression atmosphérique dans d'une part un réacteur plasma de décharge à barrière diélectrique (DBD) pulsée et un réacteur catalytique utilisés séparément et d'autre part, dans un réacteur hybride associant le réacteur plasma aux catalyseurs dans deux configurations: le catalyseur au coeur de la décharge et le catalyseur en post-décharge. Les catalyseurs sont à base de Pd, Mn, Cu, et Co supportés sur des billes de Al2O3. Ils ont été caractérisés par ICP-OES, TEM/EDX, XRD, XPS, et DRIFTS. L’efficacité de conversion des COV, la sélectivité en CO/CO2, ainsi que la nature et les concentrations des produits formés pour les trois molécules avec les trois systèmes ont été étudiées en fonction de la température du gaz, de l'énergie injectée, de la concentration des COV, de la taille du support, du type de métal et sa teneur, et de la vitesse volumique horaire. Dans tous les cas, l’activation des catalyseurs à basse température a été démontrée quand ces derniers sont couplés au plasma et les principaux produits de réaction identifiés et quantifiés par spectroscopie infrarouge à transformée de Fourier. Le couplage plasma-catalyseur améliore de façon significative l’efficacité de conversion du méthane, du propène, et du toluène dans l’air ainsi que la sélectivité en sous-produits. L'effet de synergie entre le plasma et les catalyseurs pour la conversion des COV a été démontré dès lors que le plasma est généré directement au sein du réacteur catalytique. / The focus of this thesis is the application of non-thermal plasma and catalysis in chemical processing, in particular for the removal of Volatile Organic Compounds (VOC) diluted in air. In a first part, the oxidation of three pollutants (methane, propene, and toluene) is studied experimentally in a pulsed dielectric barrier discharge (DBD) reactor and in a catalyst reactor working independently. In a second part, a hybrid plasma-catalyst reactor either in a single-stage or in a two-stages configuration, in which the catalyst is located inside or downstream from the plasma reactor, respectively. Catalyst materials based on Pd, Mn, Cu, and Co supported on alumina beads were tested and characterized by ICP-OES, TEM/EDX, XRD, XPS, and DRIFTS. Products were analyzed and quantified by infrared spectroscopy. Achieved VOCs removal efficiencies and CO/CO2 selectivity, as well as nature and concentrations of the formed products, were evaluated as function of many factors, particularly the specific input energy, the gas temperature, the initial VOCs concentration, the nature of catalyst (size support, metal loading), and the hourly space velocity. It has been successfully demonstrated that the combination of plasma and catalyst in the both configurations has many benefits compared to traditional thermal-catalysis and plasma alone treatment including a lowering of the catalyst operating temperature, an improvement of the conversion of VOCs at similar temperatures, and a better end-products selectivity and energy efficiency. The mutual interaction lead to a synergistic effect in plasma-catalysis especially when the discharge is in direct contact with the catalyst whatever the VOCs studied.

Background: The COVID-19 pandemic is caused by the SARS-CoV-2 virus, which enter the host cells through interactions between the receptor-binding domain (RBD) on the S-protein and the ACE-2 receptor on the host cell. A novel type of vaccine strategy is peptide vaccines, with great potential as a faster and more selective approach to conventional vaccine development. This study focuses on the possibility of generating an antibody response through synthetic peptides harboring B cell epitopes.  Aim: This project aims to investigate the potential of immunogenic peptides to generate an antibody response when used as synthetically produced peptides. As proof-of-concept, the project studies the interactions between previously identified monoclonal antibodies with defined B cell epitopes and the corresponding peptide sequences.  Method: The interactions are evaluated by different ELISA experiments. The candidate peptides are additionally investigated on their binding to polyclonal serum with established S reactive antibodies. Furthermore, the project includes synthesis of one peptide by solid phase peptide synthesis. Results: The ELISA experiments presented no interaction between the synthetic peptides and the monoclonal antibodies or human sera.  Conclusion: The project fulfilled its aim to study the interaction between the B cell epitopes and the monoclonal antibodies. However, no binding was observed. Despite the many advantages in production and stability, development of B cell epitope vaccines come with many challenges. Future will entail if synthetic peptides harboring B cell epitopes can be used as vaccines, or if peptide vaccines will be a focus when a T cell response is to be induced.